Concepedia

Author

Robert A. Mullinax

The University of Texas MD Anderson Cancer Center

Also Known As

Robert A Mullinax, Robert A. Mullinax, Robert Mullinax

19

Publications

2.3K

Citations

10

H-Index

21

Concepts

All Affiliations

The University of Texas MD Anderson Cancer CenterHarvard UniversityBeth Israel Deaconess Medical Center
RA

About

Robert A. Mullinax is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, cancer research, and systems biology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

1.9K

2

Public Health

1

1

700

3

Cell Biology

1

1

263

4

Endocrinology

1

1

700

5

Obstetrics

1

1

700

Robert A. Mullinax

×

9

Publications

2.3K

Citations

9

H-Index

YearCitations

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

Jennifer R. Molina, Yuting Sun, Marina Protopopova,

Nature Medicine

2018

903

Subgroup of Reproductive Functions of Progesterone Mediated by Progesterone Receptor-B Isoform

Biserka Mulac‐Jeričević, Robert A. Mullinax, Francesco J. DeMayo,

Science

2000

700

Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer

Yonathan Lissanu Deribe, Yuting Sun, Christopher Terranova,

Nature Medicine

2018

263

Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib

Yuting Sun, Brooke A. Meyers, Barbara Czakó,

Cancer Research

2020

101

Regulators of the Proteasome Pathway, Uch37 and Rpn13, Play Distinct Roles in Mouse Development

Amin Al-Shami, Kanchan G. Jhaver, Peter Vogel,

PLoS ONE

2010

88

Discovery of IPN60090, a Clinical Stage Selective Glutaminase-1 (GLS-1) Inhibitor with Excellent Pharmacokinetic and Physicochemical Properties

Michael Soth, Kang Le, Maria Emilia Di Francesco,

Journal of Medicinal Chemistry

2020

88

Functional Genomics Reveals Synthetic Lethality between Phosphogluconate Dehydrogenase and Oxidative Phosphorylation

Yuting Sun, Madhavi Bandi, Timothy Lofton,

Cell Reports

2019

67

Sequential Administration of XPO1 and ATR Inhibitors Enhances Therapeutic Response in TP53-mutated Colorectal Cancer

Akira Inoue, Frederick S. Robinson, Rosalba Minelli,

Gastroenterology

2021

36

Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R

Barbara Czakó, Joseph R. Marszalek, Jason P. Burke,

Journal of Medicinal Chemistry

2020

18

Page 1